Paul Gonzales

434 total citations
19 papers, 360 citations indexed

About

Paul Gonzales is a scholar working on Oncology, Molecular Biology and Genetics. According to data from OpenAlex, Paul Gonzales has authored 19 papers receiving a total of 360 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 7 papers in Molecular Biology and 4 papers in Genetics. Recurrent topics in Paul Gonzales's work include Cancer, Hypoxia, and Metabolism (4 papers), Glioma Diagnosis and Treatment (3 papers) and Microtubule and mitosis dynamics (3 papers). Paul Gonzales is often cited by papers focused on Cancer, Hypoxia, and Metabolism (4 papers), Glioma Diagnosis and Treatment (3 papers) and Microtubule and mitosis dynamics (3 papers). Paul Gonzales collaborates with scholars based in United States and Switzerland. Paul Gonzales's co-authors include Roman Sakowicz, Stephanie Roth, Robert V. Moody, John C. Chabala, Christophe Béraud, Kenneth W. Wood, Jeffrey T. Finer, Yan Lee, Anne Crompton and Steve Weitman and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Research.

In The Last Decade

Paul Gonzales

18 papers receiving 354 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Paul Gonzales United States 7 219 182 100 47 36 19 360
Miryam Pastor Spain 8 255 1.2× 97 0.5× 53 0.5× 38 0.8× 46 1.3× 11 362
Lorianne S. Turner United States 8 493 2.3× 167 0.9× 77 0.8× 37 0.8× 76 2.1× 9 545
Dong-Jun Lin China 11 277 1.3× 107 0.6× 87 0.9× 76 1.6× 24 0.7× 11 420
Frédéric Elustondo United Kingdom 5 362 1.7× 208 1.1× 102 1.0× 53 1.1× 75 2.1× 5 505
Jeannene Butler United States 6 291 1.3× 117 0.6× 111 1.1× 28 0.6× 19 0.5× 8 417
Ayman Mahdy United States 5 359 1.6× 115 0.6× 64 0.6× 21 0.4× 50 1.4× 6 417
Su‐Fern Tan United States 16 348 1.6× 67 0.4× 101 1.0× 52 1.1× 18 0.5× 29 477
Mahesh V. Padval United States 8 227 1.0× 75 0.4× 190 1.9× 65 1.4× 9 0.3× 22 482
Diana M. González‐Gironès Spain 10 260 1.2× 37 0.2× 61 0.6× 52 1.1× 17 0.5× 12 336
Pedro Torres‐Ayuso United States 13 268 1.2× 73 0.4× 74 0.7× 74 1.6× 20 0.6× 20 406

Countries citing papers authored by Paul Gonzales

Since Specialization
Citations

This map shows the geographic impact of Paul Gonzales's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul Gonzales with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul Gonzales more than expected).

Fields of papers citing papers by Paul Gonzales

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paul Gonzales. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul Gonzales. The network helps show where Paul Gonzales may publish in the future.

Co-authorship network of co-authors of Paul Gonzales

This figure shows the co-authorship network connecting the top 25 collaborators of Paul Gonzales. A scholar is included among the top collaborators of Paul Gonzales based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paul Gonzales. Paul Gonzales is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Gonzales, Paul, et al.. (2023). The devolution of a mature plasma cell dyscrasia into a fatal plasmablastic lymphoma. 9(2). 7–14. 1 indexed citations
2.
Cimino, Patrick J., Lan Huang, Lihua Du, et al.. (2019). Plinabulin, an inhibitor of tubulin polymerization, targets KRAS signaling through disruption of endosomal recycling. Biomedical Reports. 10(4). 218–224. 29 indexed citations
3.
Gonzales, Paul, et al.. (2019). Successful Modified Therapy in a Patient with Probable Infection-Associated Hemophagocytic Lymphohistiocytosis. SHILAP Revista de lepidopterología. 2019. 1–6.
4.
Wang, Tong, Paul Gonzales, Haiyong Han, et al.. (2019). Abstract LB-058: GB-3103, an epigenetic immunomodulator, shows potent antitumor activity against tumors harboring dual loss of SMARCA4/SMARCA2 ATPases. Cancer Research. 79(13_Supplement). LB–58. 1 indexed citations
5.
6.
Sagert, Jason, Thao Nguyen, Matthias John, et al.. (2018). Abstract 2551: Allogeneic CRISPR engineered anti CD70 CAR T cells demonstrate potent preclinical activity against both solid and hematological cancer cells. Cancer Research. 78(13_Supplement). 2551–2551. 1 indexed citations
7.
Gonzales, Paul, et al.. (2017). Everolimus Implicated in Case of Severe Gastrointestinal Hemorrhage. Case Reports in Oncological Medicine. 2017(1). 3657812–3657812. 6 indexed citations
8.
Bussey, Kimberly J., et al.. (2016). Targeting polo‐like kinase 1, a regulator of p53, in the treatment of adrenocortical carcinoma. Clinical and Translational Medicine. 5(1). 1–1. 26 indexed citations
9.
Barrett, John, et al.. (2016). IMST-07. LOCAL REGULATED IL-12 EXPRESSION AS AN IMMUNOTHERAPY FOR THE TREATMENT OF PONTINE GLIOMA. Neuro-Oncology. 18(suppl_6). vi87–vi87. 2 indexed citations
10.
Barrett, John, Hongliang Cai, Margaret Murray, et al.. (2016). 509. Regulated Expression of IL-12 as Gene Therapy Concomitant with Blockade of PD-1 for Treatment of Glioma. Molecular Therapy. 24. S203–S203. 1 indexed citations
11.
Wang, Tong, Megan L. Goodall, Paul Gonzales, et al.. (2015). Synthesis of Improved Lysomotropic Autophagy Inhibitors. Journal of Medicinal Chemistry. 58(7). 3025–3035. 33 indexed citations
12.
Theise, Neil D., et al.. (2015). Glucocorticoid receptor antagonist Org34517 as a chemosensitizing agent for ovarian cancer.. Journal of Clinical Oncology. 33(15_suppl). e16556–e16556. 1 indexed citations
13.
Wang, Tong, et al.. (2013). Identification of novel HDAC inhibitors through cell based screening and their evaluation as potential anticancer agents. Bioorganic & Medicinal Chemistry Letters. 23(17). 4790–4793. 21 indexed citations
14.
Kim, Jung‐Han, Paul Gonzales, Michael T. Barrett, et al.. (2012). Abstract 978: Inhibition of Polo-like kinase 1 as a strategy in the treatment of adrenocortical carcinoma. Cancer Research. 72(8_Supplement). 978–978. 1 indexed citations
15.
Demeure, Michael J., Shripad Sinari, David W. Mount, et al.. (2011). Preclinical Investigation of Nanoparticle Albumin-Bound Paclitaxel as a Potential Treatment for Adrenocortical Cancer. Annals of Surgery. 255(1). 140–146. 18 indexed citations
16.
Demeure, Michael J., Paul Gonzales, Kathleen E. DelGiorno, et al.. (2008). Pre-clinical evidence for nab-paclitaxel efficacy in the treatment of adrenocortical cancer. Journal of Clinical Oncology. 26(15_suppl). 22070–22070. 1 indexed citations
17.
Gonzales, Paul, et al.. (2007). The combination of IMO-2055, a synthetic agonist of toll-like receptor-9 (TLR9), and the multikinase inhibitor sorafenib tosylate demonstrate enhanced antitumor activity in a human non-small cell lung cancer xenograft model. Cancer Research. 67. 4771–4771. 1 indexed citations
18.
Sakowicz, Roman, Jeffrey T. Finer, Christophe Béraud, et al.. (2004). Antitumor Activity of a Kinesin Inhibitor. Cancer Research. 64(9). 3276–3280. 215 indexed citations
19.
Salzman, Andrew L., Michael J. Menconi, Naoki Unno, et al.. (1994). 234; NITRIC OXIDE (NO) DILATES TIGHT JUNCTIONS, and DEPLETES ATP IN CULTURED INTESTINAL EPITHELIA. Shock. 1(Supplement). 65–65. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Miryam Pastor Breakdown of academic impact, for papers by Lorianne S. Turner Breakdown of academic impact, for papers by Dong-Jun Lin Breakdown of academic impact, for papers by Frédéric Elustondo Breakdown of academic impact, for papers by Jeannene Butler Breakdown of academic impact, for papers by Ayman Mahdy Breakdown of academic impact, for papers by Su‐Fern Tan Breakdown of academic impact, for papers by Mahesh V. Padval Breakdown of academic impact, for papers by Diana M. González‐Gironès Breakdown of academic impact, for papers by Pedro Torres‐Ayuso
Rankless by CCL
2026